% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • b_leaguered b_leaguered Feb 15, 2014 8:38 AM Flag

    The Best Biotech Takeover Targets for 2014

    See thelifesciencesreportDOTcom

    "Large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies—and their phase 2 or phase 3 drugs."

    This could be the biggest year ever for investing in biotech takeover targets—all due to the patent cliff.

    Sanofi (NYSE ADR: SNY), Novartis AG (NYSE ADR: NVS), Roche Holding Ltd. (RHHBY), AstraZeneca PLC (NYSE ADR: AZN), and Eli Lilly & Co. (NYSE: LLY)will all be losing more than $6 billion each in annual revenue this year due to expiring patents.

    The ideal candidates are small-cap biotech firms whose pipelines include late-stage drug candidates or other promising pharmaceuticals.

    With that criteria in mind, here are six small-cap biotech firms on the list of takeover targets to watch in 2014. . .

    Biotech Takeover Targets in 2014
    (top of the list)

    Insmed Inc. (Nasdaq: INSM) primarily develops inhalation therapies for the treatment of lung diseases. Insmed's most notable project is ARIKACE, an inhaled antibiotic for patients suffering from cystic fibrosis and non-tuberculous mycobacteria. Currently, ARIKACE is in phase II trials in the United States and phase III trials in Canada and Europe.

    INSM stock has gained an impressive 241% in the last year and currently trades at $19.73. Insmed has a market cap of just $772 million, which also makes it an attractive takeover option for large-cap pharmaceutical companies.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
19.44+1.04(+5.65%)Oct 2 4:00 PMEDT